The clinical use of agents with NF‐κB activity is currently restricted to hematological malignancies such as multiple myeloma where proteasome inhibitors such as bortezomib and related drugs block NF‐κB signaling among other targets [31]. Here, NFKB1 is linked to AL amyloidosis.